Stephen Willey
Stock Analyst at Stifel
(3.08)
# 1,204
Out of 4,759 analysts
127
Total ratings
36.96%
Success rate
2.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stephen Willey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Maintains: Buy | $12 → $10 | $2.33 | +329.18% | 5 | Feb 28, 2025 | |
| GERN Geron | Maintains: Buy | $8 → $4 | $1.73 | +131.21% | 3 | Feb 27, 2025 | |
| INSM Insmed | Maintains: Buy | $97 → $96 | $74.89 | +28.19% | 6 | Feb 21, 2025 | |
| EXEL Exelixis | Maintains: Hold | $30 → $36 | $38.58 | -6.69% | 17 | Feb 12, 2025 | |
| INCY Incyte | Maintains: Hold | $75 → $77 | $70.79 | +8.77% | 5 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $34 → $36 | $13.86 | +159.74% | 4 | Jan 29, 2025 | |
| IGMS IGM Biosciences | Downgrades: Hold | $27 → $2.5 | $1.32 | +89.39% | 7 | Jan 10, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $5 → $4 | $0.35 | +1,037.01% | 2 | Nov 14, 2024 | |
| ZYME Zymeworks | Maintains: Buy | $21 → $28 | $12.00 | +133.33% | 6 | Oct 28, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Buy | $47 | $16.55 | +183.99% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.10 | +263.64% | 7 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $34 → $3 | $1.84 | +63.04% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $6 → $1.5 | $0.44 | +244.04% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $29 → $7 | $2.27 | +208.37% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $7 | $2.40 | +191.67% | 10 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $12 | $1.00 | +1,100.00% | 4 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $4 | $1.66 | +140.96% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $62 | $36.50 | +69.86% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.84 | +878.26% | 2 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $2.69 | +234.57% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.40 | +252.94% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $228 → $288 | $1.95 | +14,669.23% | 4 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $21 | $0.78 | +2,595.76% | 2 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $4 | $0.39 | +920.93% | 7 | Jul 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $123 | $244.52 | -49.70% | 3 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $48 → $47 | $33.81 | +39.01% | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $102 → $109 | $72.23 | +50.91% | 3 | Aug 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Hold | n/a | $17.64 | - | 2 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $0.27 | +9,074.31% | 5 | Mar 7, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $23 | $6.15 | +273.98% | 5 | Feb 7, 2018 |
AbCellera Biologics
Feb 28, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $2.33
Upside: +329.18%
Geron
Feb 27, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.73
Upside: +131.21%
Insmed
Feb 21, 2025
Maintains: Buy
Price Target: $97 → $96
Current: $74.89
Upside: +28.19%
Exelixis
Feb 12, 2025
Maintains: Hold
Price Target: $30 → $36
Current: $38.58
Upside: -6.69%
Incyte
Feb 10, 2025
Maintains: Hold
Price Target: $75 → $77
Current: $70.79
Upside: +8.77%
Nurix Therapeutics
Jan 29, 2025
Maintains: Buy
Price Target: $34 → $36
Current: $13.86
Upside: +159.74%
IGM Biosciences
Jan 10, 2025
Downgrades: Hold
Price Target: $27 → $2.5
Current: $1.32
Upside: +89.39%
X4 Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $0.35
Upside: +1,037.01%
Zymeworks
Oct 28, 2024
Maintains: Buy
Price Target: $21 → $28
Current: $12.00
Upside: +133.33%
Bicara Therapeutics
Oct 8, 2024
Initiates: Buy
Price Target: $47
Current: $16.55
Upside: +183.99%
Aug 20, 2024
Maintains: Buy
Price Target: $8 → $4
Current: $1.10
Upside: +263.64%
Jul 9, 2024
Downgrades: Hold
Price Target: $34 → $3
Current: $1.84
Upside: +63.04%
May 15, 2024
Downgrades: Hold
Price Target: $6 → $1.5
Current: $0.44
Upside: +244.04%
May 10, 2024
Downgrades: Hold
Price Target: $29 → $7
Current: $2.27
Upside: +208.37%
Apr 12, 2024
Maintains: Hold
Price Target: $7
Current: $2.40
Upside: +191.67%
Mar 21, 2024
Maintains: Buy
Price Target: $15 → $12
Current: $1.00
Upside: +1,100.00%
Dec 19, 2023
Maintains: Buy
Price Target: $3 → $4
Current: $1.66
Upside: +140.96%
Dec 18, 2023
Maintains: Buy
Price Target: $53 → $62
Current: $36.50
Upside: +69.86%
May 12, 2023
Maintains: Buy
Price Target: $21 → $18
Current: $1.84
Upside: +878.26%
Jan 27, 2023
Initiates: Buy
Price Target: $9
Current: $2.69
Upside: +234.57%
Nov 28, 2022
Initiates: Buy
Price Target: $12
Current: $3.40
Upside: +252.94%
Jun 26, 2020
Downgrades: Hold
Price Target: $228 → $288
Current: $1.95
Upside: +14,669.23%
Mar 17, 2020
Maintains: Buy
Price Target: $22 → $21
Current: $0.78
Upside: +2,595.76%
Jul 29, 2019
Downgrades: Hold
Price Target: $10 → $4
Current: $0.39
Upside: +920.93%
Aug 13, 2018
Maintains: Buy
Price Target: $125 → $123
Current: $244.52
Upside: -49.70%
Aug 8, 2018
Maintains: Hold
Price Target: $48 → $47
Current: $33.81
Upside: +39.01%
Aug 3, 2018
Maintains: Buy
Price Target: $102 → $109
Current: $72.23
Upside: +50.91%
Jun 25, 2018
Terminates: Hold
Price Target: n/a
Current: $17.64
Upside: -
Mar 7, 2018
Maintains: Buy
Price Target: $23 → $25
Current: $0.27
Upside: +9,074.31%
Feb 7, 2018
Maintains: Buy
Price Target: $20 → $23
Current: $6.15
Upside: +273.98%